AIM's Rabies Vaccine Nears Market Entry, Signals Strong Valuation Rebound
April 08, 2025 | 11:23
AIM Vaccine Co., Ltd., announced on April 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Administration for market registration.
AIM Vaccine Cuts 2024 Losses by 90%, Paving the Way for Breakthrough Growth
March 31, 2025 | 07:00
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
March 24, 2025 | 14:43
AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 23, 2025.
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials
March 10, 2025 | 07:00
AIM Vaccine Co., Ltd., a leading PRC vaccine company, published an announcement on March 9, 2025 , the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medical Products Administration.
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
February 27, 2025 | 07:00
The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine announced on February 26 that its self-developed mRNA RSV vaccine has recently received clinical trial approval from the U.S. Food and Drug Administration.
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
February 25, 2025 | 07:00
As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in China is in full swing.
Latest News
Mobile Version